Finasteride


Article Author:
Patrick Zito


Article Editor:
Kirin Syed


Editors In Chief:
Melissa Max
Danyae Lee
Manouchkathe Cassagnol


Managing Editors:
Avais Raja
Orawan Chaigasame
Carrie Smith
Abdul Waheed
Khalid Alsayouri
Trevor Nezwek
Radia Jamil
Patrick Le
Anoosh Zafar Gondal
Saad Nazir
William Gossman
Hassam Zulfiqar
Steve Bhimji
John Shell
Matthew Varacallo
Heba Mahdy
Ahmad Malik
Sarosh Vaqar
Mark Pellegrini
James Hughes
Beata Beatty
Nazia Sadiq
Hajira Basit
Phillip Hynes
Tehmina Warsi


Updated:
12/19/2018 6:14:23 AM

Indications

In 1947, James Hamilton of Yale University published an article on male hormone stimulation as a prerequisite to common baldness after examining 104 men with testicular insufficiency. In 1974, Julianne Imperato-McGinley, of Cornell University, published reports on Caribbean children that had a mutation leading to deficiencies in 5-alpha-reductase and dihydrotestosterone. When these male children matured, they had smaller prostate sizes and lack of male pattern baldness. These observations and findings ultimately led to the development of finasteride.[1][2][3]

Finasteride is an FDA-approved pharmacologic agent for the treatment of benign prostate hyperplasia and androgenic alopecia (male pattern hair loss) in men. Finasteride was first used in 1992 to treat benign prostate hyperplasia at a dose of 5 mg. In 1998, it was approved to treat male pattern hair loss at a dose of 1 mg. Finasteride has also been used to treat signs of hyperandrogenism such as hirsutism and may be used in transgender women in combination with estrogen for its anti-androgen properties.

Mechanism of Action

Finasteride is a competitive inhibitor of types II and III 5-alpha-reductase isoenzyme, resulting in inhibition of the conversion of testosterone to dihydrotestosterone (DHT). Finasteride has minimal selectivity for the type I 5-alpha-reductase enzyme. The type I 5-alpha-reductase isomer is found in sebaceous glands, sweat glands, dermal papillae cells, and epidermal and follicular keratinocytes. Type II is found in the outer root sheaths of hair follicles, the epididymis, vas deferens, seminal vesicles, and prostate.[4][5][6]

Finasteride has been shown to reduce prostatic DHT levels by upwards of 90% and serum DHT levels by upwards of 70%. However, increasing the dose does not necessarily result in greater serum reduction. Dutasteride, in comparison, inhibits all three 5-alpha-reductase isoenzymes leading to a 99% reduction in serum DHT levels. In the treatment of androgenic alopecia where finasteride does not lead to a 100% reduction in DHT, hair loss is slowed but not completely halted. In the treatment of benign prostate hyperplasia, long-term use of finasteride has been associated with a reduction in prostatic volume, thereby providing relief from bothersome urinary symptoms attributed to an enlarged gland. Previously published literature has demonstrated reduced risk of urinary retention and delayed the need for surgical intervention.

Pharmacokinetics 

The bioavailability of finasteride is approximately 65% and is not affected by food. Finasteride is approximately 90% protein bound with a volume of distribution of 76 L at steady state. Upon discontinuation of finasteride, DHT levels return to normal within 14 days. In patients being treated for benign prostate hyperplasia, prostate volume returns to baseline within three months; patients being treated for androgenic alopecia have a reversal of hair count within 12 months.

Finasteride undergoes extensive metabolism in the liver (hepatic metabolism) via the cytochrome P450 enzyme system, specifically CYP3A4, into two active metabolites with less than 20% of the activity of finasteride. Finasteride has a half-life of elimination from the serum of 5 to 6 hours with a range of 3 to 16 hours. In elderly patients (greater than 70 years of age), the half-life can be prolonged to 8 hours. In comparison to dutasteride, the half-life of finasteride is markedly shorter. Dutasteride has a half-life of 4 to 5 weeks. 

Finasteride is eliminated as metabolites, 57% in the feces and 39% in the urine.

Administration

Finasteride is available as a 1 mg tablet or a 5 mg tablet for oral use. Each dose has a different indication. As much as six months of continued treatment may be necessary to assess the benefit in treatment.

Recommended Dosages

  • Benign prostatic hyperplasia: 5 mg once daily (as a single agent or combined with an alpha-blocker).
  • Androgenic alopecia (male pattern baldness): 1 mg once daily.
  • Hirsutism (female, idiopathic and related to polycystic ovary syndrome): 5 mg once daily or 2.5 mg once daily. This is an off-label use.

Adverse Effects

Common adverse effects associated with finasteride include loss of libido, erectile dysfunction (2% to 4%), decreased ejaculatory volume, and gynecomastia. It has also been associated with orthostatic hypotension. This can be additive in patients who are taking concomitant alpha blockers. Finasteride has been reported to cause orthostatic hypotension in approximately 9% of users as monotherapy, and as high as 18% with combined therapy. Therefore, appropriate patient counseling should be undertaken.

Post-finasteride syndrome (PFS) has recently been reported. This refers to the continuation of adverse effects despite discontinuation of therapy. Further investigational studies to better understand post-finasteride syndrome are currently underway.

The impact of finasteride on fertility has also been examined from the urologic and dermatologic practitioners that utilize the medication (in different doses and for different indications). Thus far there is minimal data to support the association of permanent infertility with use of low dose 1 mg finasteride. The effects of low dose finasteride on fertility appear to be reversible as various studies have demonstrated improved fertility and sperm parameters in those who discontinued therapy. However, fertility may be impacted by the use of the higher 5-mg dose. Not all users experience issues with fertility, and many users of the medication are still able to conceive. 

Additionally, finasteride has been linked to symptoms of dizziness, weakness, dyspnea, rhinitis, and skin rash.

Contraindications

  • Finasteride is contraindicated in those with hypersensitivity to any component of the formulation. 
  • Finasteride is contraindicated in children.
  • Furthermore, finasteride is contraindicated in pregnant women or women of childbearing age.
  • Pregnant women are advised to avoid contact with tablets that have been crushed or broken as animal reproduction studies resulted in abnormality of external male genitalia. If used for the off-label management of hirsutism in female patients with polycystic ovary syndrome, adequate contraception is recommended by the American College of Gynecology.
  • Blood donation is contraindicated in those currently taking finasteride and up to 6 months following the last dose of finasteride.

Monitoring

No specific laboratory monitoring guidelines exist for finasteride. However, prostate-specific antigen is assessed in men with benign prostate hyperplasia and surveillance for prostate cancer. Due to the decrease in prostatic volume at the 5-mg dose, there is an expected decrease in serum prostate-specific antigen levels. Therefore, it is recommended to obtain baseline prostate-specific antigen levels before initiating therapy. Practitioners should be cognizant of serum prostate-specific antigen values in patients using finasteride. Serum labs values are often multiplied by 2 to estimate a more accurate approximation of levels.[7][8]

There has been some controversy regarding the role of finasteride in the development of prostate cancer. The Prostate Cancer Prevention Trial (PCPT) was a landmark study that compared daily finasteride to placebo therapy in over 18,000 men aged 55 and older who were followed for seven years. The study ultimately concluded that finasteride was associated with a 25% reduction in the prevalence of prostate cancer. However, it was also associated with an increased rate of detection of high-grade prostate cancer. The FDA eventually placed a black box warning on the medication safety label, resulting in a negative impact on prescribing patterns of the drug. There is a considerable consensus in the field that the increased rate of high-grade cancer in the PCPT may be the result of confounding factors and detection bias. However, it cannot be excluded with certainty.

The American Society of Clinical Oncology (ASCO) and American Urological Association (AUA) released a joint statement in 2008 and developed a clinical practice guideline to assist physicians and patients with making informed decisions after reviewing the risks and benefits of the medication.

The AUA supports the use of finasteride as a treatment option for men with benign prostate hyperplasia and shared decision-making.

Toxicity

Overdoses of finasteride resulting in clinically significant toxicity have not been reported. However, overdoses are expected to be an extension of previously reported adverse drug effects, including orthostatic hypotension.

Enhancing Healthcare Team Outcomes

Finasteride is an FDA-approved pharmacologic agent for the treatment of benign prostate hyperplasia and androgenic alopecia (male pattern hair loss) in men. The drug is also sometimes used to treat hyperandrogenism and hirsutism. Healthcare workers including nurse practitioners who prescribe this medication should screen all males for prostate cancer while on this agent,


Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Finasteride - Questions

Take a quiz of the questions on this article.

Take Quiz
What is the mechanism of action of finasteride?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following is known to inhibit 5-alpha reductase?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following drugs would be most appropriate for treating benign prostatic hyperplasia?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which drug reduces the size of the prostate?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 59-year-old former, competitive weightlifter complains of a diminished urine stream and reports several trips to the bathroom to urinate at night resulting in minimal voids. A digital rectal examination reveals an enlarged prostate. Prostate-specific antigen levels are within normal limits. The patient is started on finasteride 5 mg by mouth daily, and he reports symptomatic resolution 6 months after initiating therapy. Which statement below is false regarding finasteride?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following drugs should not be handled by females who are pregnant or could become pregnant?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following accounts for the therapeutic action of finasteride in treating benign prostatic hyperplasia?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following drugs is indicated for the management of benign prostatic hyperplasia?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up

Finasteride - References

References

Zabkowski T,Saracyn M, Drug adherence and drug-related problems in pharmacotherapy for lower urinary tract symptoms related to benign prostatic hyperplasia. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society. 2018 Aug;     [PubMed]
Andrade C, Why Odds Ratios Can Be Tricky Statistics: The Case of Finasteride, Dutasteride, and Sexual Dysfunction. The Journal of clinical psychiatry. 2018 Nov 27;     [PubMed]
Dai JY,LeBlanc M,Goodman PJ,Lucia MS,Thompson IM,Tangen CM, Case-only Methods Identified Genetic Loci Predicting a Subgroup of Men with Reduced Risk of High-grade Prostate Cancer by Finasteride. Cancer prevention research (Philadelphia, Pa.). 2018 Dec 11;     [PubMed]
Shin JW,Chung EH,Kim MB,Kim TO,Kim WI,Huh CH, Evaluation of long-term efficacy of finasteride in Korean men with androgenetic alopecia using the basic and specific classification system. The Journal of dermatology. 2018 Dec 7;     [PubMed]
Almohanna HM,Perper M,Tosti A, Safety concerns when using novel medications to treat alopecia. Expert opinion on drug safety. 2018 Nov;     [PubMed]
Azarchi S,Bienenfeld A,Lo Sicco K,Marchbein S,Shapiro J,Nagler AR, Androgens in Women: Hormone modulating therapies for skin disease (Part II). Journal of the American Academy of Dermatology. 2018 Oct 9;     [PubMed]
Shin YS,Karna KK,Choi BR,Park JK, Finasteride and Erectile Dysfunction in Patients with Benign Prostatic Hyperplasia or Male Androgenetic Alopecia. The world journal of men's health. 2018 Aug 10;     [PubMed]
Andy G,John M,Mirna S,Rachita D,Michael K,Maja K,Aseem S,Zeljana B, Controversies in the treatment of androgenetic alopecia: The history of finasteride. Dermatologic therapy. 2018 Sep 25;     [PubMed]

Disclaimer

The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of Pharmacy-Pharmacotherapy. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for Pharmacy-Pharmacotherapy, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in Pharmacy-Pharmacotherapy, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of Pharmacy-Pharmacotherapy. When it is time for the Pharmacy-Pharmacotherapy board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study Pharmacy-Pharmacotherapy.